ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the launch of Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg doses, a generic version of the branded drug Cymbalta.

U.S. annual sales for Duloxetine Delayed-Release Capsules totaled approximately $247 million, based on August 2026 moving annual total data from IQVIA.

Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals, said the launch provides "another alternative of a widely used therapy in a limited player market to assure stable supply."